Vontobel Holding’s Lexicon Pharmaceuticals LXRX Stock Holding History

Vontobel Holding’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-80,000	Closed	-$385K	–	1159
2021 Q3	$385K	Hold	80,000	–	–	﹤0.01%	871
2021 Q2	$367K	Hold	80,000	–	–	﹤0.01%	856
2021 Q1	$470K	Hold	80,000	–	–	﹤0.01%	691
2020 Q4	$274K	Buy	+80,000	New	+$153K	﹤0.01%	823

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vontobel Holding's LXRX Position: Q4 2021 in Review

Vontobel Holding sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2021, closing a stake of 80,000 shares — an estimated $385K sold.

Vontobel Holding first reported a position in LXRX in Q4 2020 and held it in 4 quarters. The position peaked at $470K in Q1 2021. 110 funds tracked by Wall St. Rank hold LXRX as of Q4 2021.

Vontobel Holding reported no remaining Lexicon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Vontobel Holding sold 80,000 Lexicon Pharmaceuticals shares in Q4 2021, an estimated $385K.
Vontobel Holding first reported a position in Lexicon Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Vontobel Holding's Lexicon Pharmaceuticals position peaked at $470K in Q1 2021.
110 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2021.

Based on Vontobel Holding's 13F filing for Q4 2021, filed 10 Feb 2022.